DOCSLIB.ORG

Electrochemical Behaviour of Flavonoids on a Surface

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Electrochemical Behaviour of Flavonoids on a Surface 44 Biomed. Papers 149 (Supplement 1), 2005 ELECTROCHEMICAL BEHAVIOUR 3/ OF FLAVONOIDS ON A SURFACE / / OF A CARBON PASTE ELECTRODE 2 4 8 / Pavel Hanuštiaka, Radka Mikelováa, O 1 5/ a, b c c 7 David Potěšil , Petr Hodek , Marie Stiborová , 1 2 René Kizeka 6/ 6 a Department of Chemistry and Biochemistry, Faculty 3 of Agronomy, Mendel University of Agriculture and 4 5 Forestry, Zemědělská 1, CZ-613 00 Brno, Czech Republic O b Department of Analytical Chemistry, Faculty of Science, Fig. 1. Flavonoid structure made of two benzene rings Masaryk University, Kotlářská 37, CZ-611 37 Brno, linked by heterocyclic pyran. Czech Republic c Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128 40 Prague, of health and could significantly support a physiological Czech Republic capacity or decrease a possibility of a disease appearing3. e-mail: [email protected] Different groups of metabolites such as phenolic acids, lignans, phytosterols, carotenoids, glucosinolates and Key words: Flavonoids/Antioxidant/Rutin/Quercetin/ also flavonoids influence human health as described Quercitrin/Diosmin/Chrysin/Carbon paste electrode/ above2. Flavonoids comprise a wide-ranging group of Square wave voltammetry plant phenols. Up to now, more than 4,000 of flavonoid compounds are known and new ones have been still dis- covering. Flavonoids are derived from heterocyclic oxy- ABSTRACT gen compound, flavan, which is formed by two benzene rings linked by heterocyclic pyran (Fig. 1). All three rings Recent papers discuss relation of flavonoid compounds could be substituted by hydroxy- or methoxy-groups and and tumour diseases. In addition it is impossible to say particular derivates differs only in degree of substitution that effect of flavonoids is positive or negative without and oxidation. We distinguish following basic structures of epidemiological studies. That is why it is necessary to flavonoids: catechins, leukoanthocyanidins, flavanons, fla- suggest a simple, low cost and sensitive technique for de- vononols, flavons and anthocyanides. Natural flavonoids termination of these compounds in biological material. occur mostly in form of O-glycoside. Existence of free The electrochemical techniques are very suitable for these aglycones is rare, but it was observed that concentration purposes. Here we suggested the electrochemical tech- of free aglycones could increase in specific conditions nique for the determination of rutin, quercetin, quercitrin, (during technological processing at high temperatures and chrysin and diosmin by square wave voltammetry using also in acidic medium) when hydrolysis of glycosides may carbon paste electrode as a working electrode. The limits proceed4, 5. of detection of the studied flavonoids were about tens of Antioxidative activity of flavonoids, which means e.g. nM, except diosmin (tens of µM). capability to scavenging of reactive oxygen species or pro- tection of LDL fractions of lipids against their oxidative modification (crucial during atherosclerosis progress), INTRODUCTION has been studying. Moreover, flavonoids have other ef- fects – anticoagulant, antiestrogenic, antiinflammatory It is common knowledge that compounds contained (digestive tract), antimicrobial, or spasmolytic (Fig. 2). in food considerably affect our health. People living in In addition opinions of the scientists markedly vary in developed country have not usually problems with insuf- case of the relation of flavonoids with tumour diseases. ficient food and nutrient intake, contrarywise, they con- Number of authors assign to them anticancer effect which sume more than need1. Therefore there is needed to take is ascertained in in vitro tests and on animal models. On care of compounds which are present in minor amount the other hand, this effect has not been proved in epide- in food as well. For example vitamins or mineral elements miological studies2, 6–8. The same scientists allege that an belong to the minor food component, but there are many anticancer activity of flavonoids could be deduced from other constituents which have both positive and nega- theirs chemical structure and that the activity appear in tive affect on health of the consumer. In relation to this, both initiatory and promotional phase of carcinogenesis. some authors speak about foodstuffs called nutraceutics2. In connection with this activity, the following mechanisms Nutraceutics represent foodstuffs that could positively af- are discussed: i) inhibition of enzymes of phase I (PIE) fect physiological functions of a human organism. To be encouraging oxidation, ii) induction of conjugating and specific, it was proved that they influence general state detoxificating enzymes of phase II, iii) direct interaction Biomed. Papers 149 (Supplement 1), 2005 45 antimicrobial effect anticoagulant effect spasmolytic effect Flavonoids antiestrogennic effect antioxidant effect elimination of reactive oxygen species Fig. 2. Scheme of possible effects of flavonoids. with DNA, iv) induction of apoptosis (programmed cell a standard cell with three electrodes. The working elec- death), v) inhibition of cell proliferation, vi) antioxidant trode was a carbon paste electrode. The reference elec- action, vii) modulation of immune system. trode was an Ag/AgCl/3M KCl electrode and the auxiliary On the contrary, there are also authors which are con- electrode was a graphite electrode. The supporting elec- vinced of carcinogen affecting of some flavonoids9, 10. They trolyte was prepared by mixing buffer components. For assert that applying of high dose of flavonoids, for exam- smoothing and baseline correction the software GPES 4.4 ple diosmin, on the one hand effectively protects forma- supplied by EcoChemie was employed. SWV experiments tion of certain adducts with DNA but on the second hand were performed at room temperature. The measurements has simultaneously genotoxic influence. It could be taken were performed using the following parameters: initial an exception that as high amount of flavonoid is not able potential = 0.1 V, end potential = 1.2 V, pulse amplitude = to achieve without food supplements. But it was found out 49.85 mV, step potential = 1.95 mV, and frequency = 180 -1 that flavonoids concentration can increase to mmol.l due Hz. Phosphate buffer (0.1 M NaH2PO4 + 0.1 M Na2HPO4, to limited resorption of them in small intestine and water pH 7.0) was used as a supporting electrolyte. The carbon resorption in large intestine6, 7. paste (about 0.5 g) was made of graphite powder (Aldrich) In this work we were concerned with suggestion of and mineral oil (Sigma; free of DNase, RNase, and pro- electroanalytical technique for determination of quercetin, tease). The ratio of the graphite powder and mineral oil quercitrin, rutin, diosmin and chrysin on the surface of was 70/30 (w/w). This paste was housed in a Teflon body a carbon paste electrode. having a 2.5-mm-diameter disk surface. Prior to measure- ments, the electrode surface was renewed by polishing it with soft filter paper. MATERIAL AND METHODS Chemicals RESULTS AND DISCUSSION Methanol, NaH2PO4, diosmin, chrysin, quercetin di- hydrate, carbon powder, and mineral oil were purchased Using of an electroanalytical approach for detection from Sigma Aldrich Chemical Corp. (St. Louis, MO, of flavonoids is rare11, 12. Analytical determination of flavo- USA). Rutin trihydrate and quercitrin dihydrate were noids is currently maintained mainly by chromatographic 13–17 15, 18, 19 from Roth GmbH (Karlsruhe, Germany). Na2HPO4 was procedures and capillary electrophoresis . Electro- purchased from Merck (Darmstadt, Germany). Solutions chemical procedures represent advantageous possibility of were prepared using ACS water from Sigma Aldrich. miniaturisation and simultaneous analysis in vivo without disruption of living organism in comparison with these Electrochemical measurements commonly used methods. Electrochemical measurements were performed with Recently, method for electrochemical determination of AUTOLAB Analyser (EcoChemie, Netherlands) con- quercetin using glassy carbon electrode was published12. nected to VA-Stand 663 (Metrohm, Switzerland), using A renewing of the electrode surface (polishing by alumi- 46 Biomed. Papers 149 (Supplement 1), 2005 /( A B /( "ACKGROUND ELECTROLYTE 1UERCITRIN /( 2UTIN C #( /( /( (/ / K / A E (/ / /( P K A E / /( / /( P / /#(/( /( / / 3CAN 3CAN /( /( / 3CAN #( (/ /( /( ±! K ±! K A ±! A E E P P 0OTENTIAL 6 0OTENTIAL 6 0OTENTIAL 6 1UERCETIN #HRYSIN $IOSMIN D E F #( /( (/ / /( /( / (/ / (/ / #( K A /( (# / / / E (/ / P K A E (/ /( 3CAN P /( 3CAN 3CAN /( / /( /( / /( / K A K E A ±! P E K ±! ±! P A K E A P E P 0OTENTIAL 6 0OTENTIAL 6 0OTENTIAL 6 Fig. 3. Square–wave voltammograms of the studied flavonoids at 10 µM concentration – a) background electrolyte, b) quercitrin, c) rutin, d) quercetin, e) chrysin and e) 100 µM of diosmin. The SWV parameters were as follows: initial potential = 0.1 V, end potential = 1.2 V, pulse amplitude = 49.85 mV, step potential = 1.95 mV, and frequency = 180 Hz. Phosphate buffer (0.1 M NaH2PO4 + 0.1 M Na2HPO4, pH 7.0) was used as a supporting electrolyte. For other details see Materials and Methods section. na, ultrasound) is the main disadvantage of this approach. signal of chrysin and diosmin were lower in comparison Therefore we suggested the method utilising carbon paste with signal of quercetin and its glycosylated derivatives electrode (CPE) for determination of quercetin, rutin, (Fig. 3d, e). The observed decrease of electrochemical quercitrin, chrysin, and
Load more

Recommended publications
  • Clinical Study Is Nonmicronized Diosmin 600Mg As Effective As
    Hindawi International Journal of Vascular Medicine Volume 2020, Article ID 4237204, 9 pages https://doi.org/10.1155/2020/4237204 Clinical Study Is Nonmicronized Diosmin 600mg as Effective as Micronized Diosmin 900mg plus Hesperidin 100mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study Marcio Steinbruch,1 Carlos Nunes,2 Romualdo Gama,3 Renato Kaufman,4 Gustavo Gama,5 Mendel Suchmacher Neto,6 Rafael Nigri,7 Natasha Cytrynbaum,8 Lisa Brauer Oliveira,9 Isabelle Bertaina,10 François Verrière,10 and Mauro Geller 3,6,9 1Hospital Albert Einstein (São Paulo-Brasil), R. Mauricio F Klabin 357/17, Vila Mariana, SP, Brazil 04120-020 2Instituto de Pós-Graduação Médica Carlos Chagas-Fundação Educacional Serra dos Órgãos-UNIFESO (Rio de Janeiro/Teresópolis- Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 3Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 4Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), Av. N. Sra. De Copacapana, 664/206, Rio de Janeiro, RJ, Brazil 22050-903 5Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Rua Prefeito Sebastião Teixeira 400/504-1, Rio de Janeiro, RJ, Brazil 25953-200 6Instituto de Pós-Graduação Médica Carlos Chagas (Rio de Janeiro-Brazil), R. General Canabarro 68/902, Rio de Janeiro, RJ, Brazil 20271-200 7Department of Medicine, Rutgers New Jersey Medical School-USA, 185 S Orange Ave., Newark, NJ 07103, USA 8Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), R. Hilário de Gouveia, 87/801, Rio de Janeiro, RJ, Brazil 22040-020 9Universidade Federal do Rio de Janeiro (UFRJ) (Rio de Janeiro-Brazil), Av.
    [Show full text]
  • The Benefits of Flavonoids in Diabetic Retinopathy
    nutrients Review The Benefits of Flavonoids in Diabetic Retinopathy 1, 1, 2,3,4,5 1,2,3,4, Ana L. Matos y, Diogo F. Bruno y, António F. Ambrósio and Paulo F. Santos * 1 Department of Life Sciences, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal; [email protected] (A.L.M.); [email protected] (D.F.B.) 2 Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal; [email protected] 3 Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal 4 Clinical Academic Center of Coimbra (CACC), 3004-561 Coimbra, Portugal 5 Association for Innovation and Biomedical Research on Light and Image (AIBILI), 3000-548 Coimbra, Portugal * Correspondence: [email protected]; Tel.: +351-239-240-762 These authors contributed equally to the work. y Received: 10 September 2020; Accepted: 13 October 2020; Published: 16 October 2020 Abstract: Diabetic retinopathy (DR), one of the most common complications of diabetes, is the leading cause of legal blindness among adults of working age in developed countries. After 20 years of diabetes, almost all patients suffering from type I diabetes mellitus and about 60% of type II diabetics have DR. Several studies have tried to identify drugs and therapies to treat DR though little attention has been given to flavonoids, one type of polyphenols, which can be found in high levels mainly in fruits and vegetables, but also in other foods such as grains, cocoa, green tea or even in red wine.
    [Show full text]
  • Chondroprotective Agents
    Europaisches Patentamt J European Patent Office © Publication number: 0 633 022 A2 Office europeen des brevets EUROPEAN PATENT APPLICATION © Application number: 94109872.5 © Int. CI.6: A61K 31/365, A61 K 31/70 @ Date of filing: 27.06.94 © Priority: 09.07.93 JP 194182/93 Saitama 350-02 (JP) Inventor: Niimura, Koichi @ Date of publication of application: Rune Warabi 1-718, 11.01.95 Bulletin 95/02 1-17-30, Chuo Warabi-shi, 0 Designated Contracting States: Saitama 335 (JP) CH DE FR GB IT LI SE Inventor: Umekawa, Kiyonori 5-4-309, Mihama © Applicant: KUREHA CHEMICAL INDUSTRY CO., Urayasu-shi, LTD. Chiba 279 (JP) 9-11, Horidome-cho, 1-chome Nihonbashi Chuo-ku © Representative: Minderop, Ralph H. Dr. rer.nat. Tokyo 103 (JP) et al Cohausz & Florack @ Inventor: Watanabe, Koju Patentanwalte 2-5-7, Tsurumai Bergiusstrasse 2 b Sakado-shi, D-30655 Hannover (DE) © Chondroprotective agents. © A chondroprotective agent comprising a flavonoid compound of the general formula (I): (I) CM < CM CM wherein R1 to R9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof, or a naturally occurring glycoside thereof is disclosed. The 00 00 above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to (Q protect cartilage, and thus, is extremely effective for the treatment of arthropathy. Rank Xerox (UK) Business Services (3. 10/3.09/3.3.4) EP 0 633 022 A2 BACKGROUND OF THE INVENTION 1 . Field of the Invention 5 The present invention relates to an agent for protecting cartilage, i.e., a chondroprotective agent, more particularly, a chondroprotective agent containing a flavonoid compound or a stereoisomer thereof, or a naturally occurring glycoside thereof.
    [Show full text]
  • 16441-16455 Page 16441 S
    S. Umamaheswari*et al. /International Journal of Pharmacy & Technology ISSN: 0975-766X CODEN: IJPTFI Available Online through Research Article www.ijptonline.com EFFECT OF FLAVONOIDS DIOSMIN, MORIN AND CHRYSIN ON CHANG LIVER CELL LINE K.S. Sridevi Sangeetha1, S. Umamaheswari1*, C. Uma Maheswara Reddy1, S. Narayana kalkura2 1 Department of Pharmacology, Faculty of Pharmacy, Sri Ramachandra University, Porur, Chennai 2Crystal Growth Centre, Anna University, Guindy, Chennai. Email: [email protected] Received on 06-08-2016 Accepted on 27-08-2016 Abstract Objective: To evaluate the effect of selected flavonoids diosmin, morin and chrysin on chang cell (normal human liver cells) line by using cell viability assay. Methods: The cell viability assay on chang cell was determined using MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5- diphenyltetrazolium bromide) assay. Diosmin, morin and chrysin were subjected in the concentration of 1.625 µM, 3.125 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM, 100 µM and 500 µM respectively. Results: The cytoprotective activity by MTT method showed that the IC 50 value of diosmin, morin and chrysin was 101.91 µM, 14.62 µM and 70.00 µM respectively. Conclusion: Out of the three flavonoids, diosmin and chrysin were proven to have very good cytoprotective activity against Chang cell line. The order of activity was found to be Disomin > Chrysin > Morin. Key words: Flavonoid, Chang cell line, Diosmin, Morin, Chrysin Introduction Plant produces different types of secondary metabolites and one such group is flavonoid. They are polyphenolic in nature and present in different part of the plant like leaves, flowers, fruits, vegetable etc.
    [Show full text]
  • Drug Bioavailability Enhancing Agents of Natural Origin (Bioenhancers) That Modulate Drug Membrane Permeation and Pre-Systemic Metabolism
    pharmaceutics Review Drug Bioavailability Enhancing Agents of Natural Origin (Bioenhancers) that Modulate Drug Membrane Permeation and Pre-Systemic Metabolism Bianca Peterson, Morné Weyers , Jan H. Steenekamp, Johan D. Steyn, Chrisna Gouws and Josias H. Hamman * Centre of Excellence for Pharmaceutical Sciences (Pharmacen™), North-West University, Potchefstroom 2520, South Africa; [email protected] (B.P.); [email protected] (M.W.); [email protected] (J.H.S.); [email protected] (J.D.S.); [email protected] (C.G.) * Correspondence: [email protected]; Tel.: +27-18-299-4035 Received: 11 December 2018; Accepted: 24 December 2018; Published: 16 January 2019 Abstract: Many new chemical entities are discovered with high therapeutic potential, however, many of these compounds exhibit unfavorable pharmacokinetic properties due to poor solubility and/or poor membrane permeation characteristics. The latter is mainly due to the lipid-like barrier imposed by epithelial mucosal layers, which have to be crossed by drug molecules in order to exert a therapeutic effect. Another barrier is the pre-systemic metabolic degradation of drug molecules, mainly by cytochrome P450 enzymes located in the intestinal enterocytes and liver hepatocytes. Although the nasal, buccal and pulmonary routes of administration avoid the first-pass effect, they are still dependent on absorption of drug molecules across the mucosal surfaces to achieve systemic drug delivery. Bioenhancers (drug absorption enhancers of natural origin) have been identified that can increase the quantity of unchanged drug that appears in the systemic blood circulation by means of modulating membrane permeation and/or pre-systemic metabolism.
    [Show full text]
  • Comparative Study on Melanin Production and Collagen Expression Profile of Polyphenols and Their Glycosides
    Indian Journal of Biochemistry & Biophysics Vol. 56, April 2019, pp. 137-143 Comparative study on melanin production and collagen expression profile of polyphenols and their glycosides Puspalata Bashyal1, Ϯ, Ha Young Jung1, Ϯ, Ramesh Prasad Pandey1, 2* & Jae Kyung Sohng1, 2* 1Department of Life Science and Biochemical Engineering; 2Department of Pharmaceutical Engineering & Biotechnology, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam -31460, Republic of Korea Received 29 May 2018; revised 29 November 2018 A total of twenty different polyphenol aglycones and their biochemically synthesized glycoside derivatives were accessed for cell toxicity, collagen synthesis and melanin content inhibition assays to illustrate the double-edged sword role of glycobiology, in particular, modification of hydroxyl group in polyphenol structure without glycone moiety over anti-aging and defense to oxidative stress in skin dermatology. All molecules at (0.1-200) µM concentration inhibited cell growth in a dose dependent manner on human dermal fibroblast (HDF) and melanoma skin cancer (B16F10) cells. At lower concentrations of (0.1-10) µM, most of the molecules were nontoxic to HDF cells, while the same molecules were toxic to B16F10 cells except astilbin (6), baicalein (13), baicalein 7-O-β-D-glucoside (14) and mangostin (18). Results showed that two molecules, quercetin (1) and diosmin (17), inhibited melanogenesis in α-melanocyte stimulating hormone (α-MSH)-stimulated melanoma skin cancer cells (B16F10) in comparison to the control at 0.1 µM concentration, indicating the possible use of these molecules in skin-whitening products. Similarly, the maintenance of collagen in HDF cells was found to be highly activated by the compound, kaempferol (11), at 1.0 µM concentration, at which the cell viability was above 95%.
    [Show full text]
  • Understanding Chronic Venous Disease: a Critical Overview of Its Pathophysiology and Medical Management
    Journal of Clinical Medicine Review Understanding Chronic Venous Disease: A Critical Overview of Its Pathophysiology and Medical Management Miguel A. Ortega 1,2,3,† , Oscar Fraile-Martínez 1,2,† , Cielo García-Montero 1,2,† , Miguel A. Álvarez-Mon 1,2,*, Chen Chaowen 1, Fernando Ruiz-Grande 4,5, Leonel Pekarek 1,2 , Jorge Monserrat 1,2 , Angel Asúnsolo 2,4,6 , Natalio García-Honduvilla 1,2,‡ , Melchor Álvarez-Mon 1,2,7,‡ and Julia Bujan 1,2,‡ 1 Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain; [email protected] (M.A.O.); [email protected] (O.F.-M.); [email protected] (C.G.-M.); [email protected] (C.C.); [email protected] (L.P.); [email protected] (J.M.); [email protected] (N.G.-H.); [email protected] (M.Á.-M.); [email protected] (J.B.) 2 Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain; [email protected] 3 Cancer Registry and Pathology Department, Hospital Universitario Principe de Asturias, 28806 Alcalá de Henares, Spain 4 Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain; [email protected] 5 Department of Vascular Surgery, Príncipe de Asturias Hospital, 28801 Alcalá de Henares, Spain 6 Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY 10027, USA 7 Citation: Ortega, M.A.; Immune System Diseases—Rheumatology and Internal Medicine Service, University Hospital Príncipe de Fraile-Martínez, O.; García-Montero, Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain * Correspondence: [email protected] C.; Álvarez-Mon, M.A.; Chaowen, C.; † These authors contributed equality in this work.
    [Show full text]
  • Inhibition of Xanthine Oxidase-Catalyzed Xanthine and 6-Mercaptopurine Oxidation by Flavonoid Aglycones and Some of Their Conjugates
    International Journal of Molecular Sciences Article Inhibition of Xanthine Oxidase-Catalyzed Xanthine and 6-Mercaptopurine Oxidation by Flavonoid Aglycones and Some of Their Conjugates Violetta Mohos 1,2 , Eszter Fliszár-Nyúl 1,2 and Miklós Poór 1,2,* 1 Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; [email protected] (V.M.); [email protected] (E.F.-N.) 2 János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary * Correspondence: [email protected]; Tel.: +36-72-536-000 (ext. 35052) Received: 23 March 2020; Accepted: 4 May 2020; Published: 5 May 2020 Abstract: Flavonoids are natural phenolic compounds, which are the active ingredients in several dietary supplements. It is well-known that some flavonoid aglycones are potent inhibitors of the xanthine oxidase (XO)-catalyzed uric acid formation in vitro. However, the effects of conjugated flavonoid metabolites are poorly characterized. Furthermore, the inhibition of XO-catalyzed 6-mercaptopurine oxidation is an important reaction in the pharmacokinetics of this antitumor drug. The inhibitory effects of some compounds on xanthine vs. 6-mercaptopurine oxidation showed large differences. Nevertheless, we have only limited information regarding the impact of flavonoids on 6-mercaptopurine oxidation. In this study, we examined the interactions of flavonoid aglycones and some of their conjugates with XO-catalyzed xanthine and 6-mercaptopurine oxidation in vitro. Diosmetin was the strongest inhibitor of uric acid formation, while apigenin showed the highest effect on 6-thiouric acid production. Kaempferol, fisetin, geraldol, luteolin, diosmetin, and chrysoeriol proved to be similarly strong inhibitors of xanthine and 6-mercaptopurine oxidation.
    [Show full text]
  • Clinical Practice Guidelines for the Management of Hemorrhoids Bradley R
    CLINICAL PRACTICE GUIDELINES The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Hemorrhoids Bradley R. Davis, M.D. • Steven A. Lee-Kong, M.D. • John Migaly, M.D. Daniel L. Feingold, M.D. • Scott R. Steele, M.D. Prepared by the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons ing the propriety of any specific procedure must be made (ASCRS) is dedicated to assuring high-quality pa- by the physician in light of all of the circumstances pre- Ttient care by advancing the science, prevention, sented by the individual patient. and management of disorders and diseases of the colon, rectum, and anus. The Clinical Practice Guidelines Com- mittee is composed of Society members who are chosen STATEMENT OF THE PROBLEM because they have demonstrated expertise in the specialty Symptoms related to hemorrhoids are very common in of colon and rectal surgery. This committee was created to the Western hemisphere and other industrialized societies. lead international efforts in defining quality care for condi- Although published estimates of prevalence are varied,1,2 tions related to the colon, rectum, and anus. This is accom- it represents one of the most common medical and surgi- panied by developing Clinical Practice Guidelines based on cal disease processes encountered in the United States, re- the best available evidence. These guidelines are inclusive sulting in >2.2-million outpatient evaluations per year.3 A and not prescriptive. Their purpose is to provide informa- large number of diverse symptoms may be, correctly or in- tion on which decisions can be made rather than to dictate correctly, attributed to hemorrhoids by both patients and a specific form of treatment.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Version 3.0, 04/2013 SUMMARY of PRODUCT CHARACTERISTICS
    Version 3.0, 04/2013 SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT [PRODUCT NAME] 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 500 mg diosmin. Excipients with known effect: Each tablet contains 4.626 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Pink (salmon) coloured, oblong, biconvex coated tablets with the inscription D500 on one side. The dimensions of diosmin tablets are 19.1 mm x 7.4 mm x 5.8 mm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications [PRODUCT NAME] is indicated in adults as a short-term treatment of symptoms of established chronic venous insufficiency (CVI) adjuvant to conventional treatment of CVI. 4.2 Posology and method of administration Posology Adults (≥ 18 years) The recommended daily dose is two tablets: one tablet at noon and one tablet in the evening, with food. The maximum duration of treatment is 2 to 3 months. Paediatric population No data are available. Method of administration For oral use. The tablets should be taken with food. 4.3 Contraindications Hypersensitivity to the active substance, other flavonoids or to any of the excipients listed in section 6.1. 3 4.4 Special warnings and precautions for use This medicinal product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. The efficacy and safety of the preparation have not been studied in the following groups/conditions, which has to be taken into account when the preparation is used: - children and adolescents (under 18 years).
    [Show full text]
  • Recommendations for the Medical Management of Chronic Venous Disease
    Supplement Phlebology 2017, Vol. 32(1S) 3–19 ! The Author(s) 2017 Recommendations for the medical Reprints and permissions: sagepub.co.uk/journalsPermissions.nav management of chronic venous DOI: 10.1177/0268355517692221 journals.sagepub.com/home/phl disease: The role of Micronized Purified Flavanoid Fraction (MPFF) Recommendations from the Working Group in Chronic Venous Disease (CVD) 2016 Ronald Bush1, Anthony Comerota2, Mark Meissner3, Joseph D. Raffetto4, Steven R. Hahn5 and Katherine Freeman6 Abstract Scope: A systematic review of the clinical literature concerning medical management of chronic venous disease with the venoactive therapy Micronized Purified Flavonoid Fraction was conducted in addition to an investigation of the hemo- dynamics and mechanism of chronic venous disease. Methods: The systematic review of the literature focused on the use of Micronized Purified Flavonoid Fraction (diosmin) which has recently become available in the US, in the management of chronic venous disease. The primary goal was to assess the level of evidence of the role of Micronized Purified Flavonoid Fraction in the healing of ulcers, and secondarily on the improvement of the symptoms of chronic venous disease such as edema. An initial search of Medline, Cochrane Database for Systematic Reviews and Google Scholar databases was conducted. The references of articles obtained in the primary search, including a Cochrane review of phlebotonics for venous insufficiency, were reviewed for additional studies. Studies were included if patients had a diagnosis of chronic venous disease documented with Doppler and Impedance Plethysmography. Studies excluded were those that had patients with arterial insufficiency (Ankle Brachial Index < .6), comorbidity of diabetes, obesity, rheumatological diseases, or if other causes of edema were present (con- gestive heart failure, renal, hepatic or lymphatic cause), or if the patient population had recent surgery or deep vein thrombosis, or had been using diuretics (in studies of edema).
    [Show full text]